You are here: Industry Insights > deaL

News List

Hints and Tips for Negotiating and Managing National and International Deals Suzanne Elvidge
October 15, 2024
Once a company has made the decision to partner or collaborate and has found the right product or the right partner – the next step is to create a strong relationship and negotiate the best possible deal for both parties.
IFM Due signs immunotherapy deal with Novartis pharmaceutical-technology
September 10, 2019
IFM Due, a subsidiary of IFM Therapeutics, has entered a collaboration and exclusive option agreement with Novartis...
Cidara and Mundipharma sign rezafungin drug development deal pharmaceutical-technology
September 05, 2019
US-based biotech Cidara Therapeutics has partnered with UK-based Mundipharma in a deal valued at more than $568m to develop and commercialise its anti-fungal drug rezafungin.
Sofinnova sells Breath Therapeutics to Zambon in $550m deal pharmaceutical-technology
July 29, 2019
Venture capital firm Sofinnova Partners has dispossessed its portfolio company Breath Therapeutics to Italian pharmaceutical firm Zambon for a total consideration of up to $550m (€500m), including a €140m upfront payment.
Merck buys Tilos Therapeutics in a $773M deal biospectrumasia
June 13, 2019
Merck Gains Portfolio of Investigational Antibodies Modulating TGFβ
AstraZeneca signs major cancer drug deal bbc
April 18, 2019
British pharmaceutical giant AstraZeneca has signed a deal with Japanese firm Daiichi Sankyo to help develop and sell the cancer drug trastuzumab deruxtecan.
AstraZeneca and Daiichi Sankyo sign $6.9bn cancer drug development deal pharmaceutical-technology
April 11, 2019
AstraZeneca has entered a deal worth up to $6.9bn with Daiichi Sankyo to develop and commercialise cancer drug trastuzumab deruxtecan...
As Amgen seeks to can Aimovig collaboration, Novartis sues to save the deal fiercepharma
April 08, 2019
Novartis and Amgen were the first to tap into a hot market with their CGRP migraine prevention drug Aimovig……
Sanofi to pay Regeneron $462 million in revised immuno-oncology deal expressbpd
January 09, 2019
The two companies said the new arrangement would give Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline, while Regeneron retains all rights to its other immuno-oncology discovery and development programmes
Bristol-Myers Squibb to buy Celgene pharmatimes
January 08, 2019
Bristol-Myers Squibb has announced that it is to acquire Celgene, in order to “create a premier innovative biopharma company” and expand its cancer and immunotherapy offering.

Previous page 1 2 3 Next page